<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase which promotes cell proliferation and survival, is abnormally overexpressed in numerous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> of epithelial origin, including <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>EGFR monoclonal antibodies have been shown to increase the median survival and are approved for the treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="15358">Histone</z:chebi> deacetylases (HDACs), frequently overexpressed in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and several <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, are another attractive targets for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Several inhibitors of HDACs (HDACi) are developed and exhibit powerful antitumor abilities </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells treated with HDACi exhibited reduced EGFR expression, thereby disturbed EGF-induced ERK and Akt phosphorylation </plain></SENT>
<SENT sid="5" pm="."><plain>HDACi also decreased the expression of SGLT1, an active <z:chebi fb="105" ids="17234">glucose</z:chebi> transporter found to be stabilized by EGFR, and suppressed the <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="6" pm="."><plain>HDACi suppressed the transcription of EGFR and class I HDACs were proved to be involved in this event </plain></SENT>
<SENT sid="7" pm="."><plain>Chromatin immunoprecipitation analysis showed that HDACi caused the dissociation of SP1, HDAC3 and CBP from EGFR promoter </plain></SENT>
<SENT sid="8" pm="."><plain>Our data suggested that HDACi could serve as a single agent to block both EGFR and HDAC, and may bring more benefits to the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> therapy </plain></SENT>
</text></document>